Amgen (AMGN) Stock Highlights

263.38 | +0.84%

2024-12-21 00:07:29

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firms therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgens biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).

Statistics

Range Today

262.21 269.61

Volume Today 13.37M

Range 1 Year

253.3 346.85

Volume 1 Year 661.41M

Range 3 Year

211.71 346.85

Volume 3 Year 2.03B

Range 10 Year

130.09 346.85

Volume 10 Year 7.54B

Highlights

Market Capitalization 141.58B (large)

Floating Shares 536.04M

Current Price 263.38

Price To Earnings 34.31

Price To Revenue 5.89

Price To Book 18.81

Earnings Per Share 7.84

Dividend Yield 3.64%

Dividend Per Share 9.52

Payout Ratio 113.41%

Performance

Latest +0.84%

1 Month -6.3%

3 Months -21.41%

6 Months -13.6%

1 Year -5.2%

3 Years +18.51%

5 Years +7.69%

10 Years +56.49%

Benchmarks

Market Capitalization

8 / 14

Gross Profits

10 / 14

Total Revenue

10 / 14

Total Rank

12 / 14

Free Cashflow

7 / 14

Performance 5 years

6 / 14

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.